Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01161706
Other study ID # 200614971
Secondary ID
Status Completed
Phase Phase 1
First received July 12, 2010
Last updated July 12, 2010
Start date July 2007
Est. completion date February 2009

Study information

Verified date July 2010
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of the investigators study is to investigate the impact of a commercial vegetable juice on dietary vegetable intake and select cardiovascular risk factors in a generally healthy population. The study was a 12 week study with 3 groups who received 0, 8 or 16 fluid ounces daily of vegetable juice, along with education on the DASH (Dietary Approaches to Stop Hypertension) diet. All participants came in for 3 study visits at 0, 6 and 12 weeks into the study.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date February 2009
Est. primary completion date December 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 40 Years to 65 Years
Eligibility ***Inclusion Criteria***

- Age 40 to 65 yrs

- Subject's body mass index is between 18.5 - 34.9 kg/m2

- Subject is willing and able to comply with the study protocols

- Subject is willing to consume a vegetable-based beverage daily for three months

***Exclusion Criteria***

- Physical signs of health impairment

- Uncontrolled diabetes or hypertension

- Pregnant or lactating

- Active tuberculosis or lung disease (i.e. COPD)

- Renal or Liver disease

- Heart Disease, which includes Cardiovascular events and Stroke

- Cushing's syndrome

- Exercise trained individuals

- History of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated with antidepressants within the last 1 year

- Anxiety medications

- Use of MAOI inhibitors within the last 1 year (e.g., phenelzine (Nardil), tranylcypromine (Parnate), etc.)

- Quality of life score of 21 or above

- Routine use of prescription drugs or over-the counter medications, which may potentially modulate the outcome of this study; including antibiotics, aspirin and aspirin-containing formulations, COX-2 inhibitors, antihistamines, corticosteroids, erectile dysfunction drugs

- Asthma (can be worsened by mild to moderate food allergies)

- Indications of substance or alcohol abuse within the last 3 years

- The volunteer is undergoing nicotine cessation therapy

- Laboratory values outside the reference range if determined to be clinically significant by Dr. M. Eric Gershwin

- Individuals with known salt-sensitive hypertension

- History of stage 1 high blood pressure defined as systolic > 140 and diastolic > 90, with or without use of HTN medications

- Multi-Vitamin use other than a One-A-Day essential

- Use of herbal or plant-based supplements; omega-3 fatty acids, and fish oils and unwilling to discontinue use while participating in the study

- Allergies to vegetables

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Intervention

Other:
Vegetable Juice
Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.

Locations

Country Name City State
United States Ragle Human Nutrition Research Center (1283 Academic Surge) Davis California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dietary Vegetable Intake 6 and 12 weeks No
Primary Dietary Nutrient Intake (vitamins & minerals) 6 and 12 weeks No
Secondary Selected Cardiovascular Risk Factors (lipids, blood pressure, TBARS/oxidative stress) 0, 6 and 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment